Predict your next investment

Wugen company logo
HEALTHCARE | Biotechnology
wugen.com

See what CB Insights has to offer

Founded Year

2018

Stage

Series B | Alive

Total Raised

$208M

Last Raised

$172M | 5 mos ago

About Wugen

Wugen is a biotechnology company that develops cell therapies for the treatment of T-cell leukemias and lymphomas, acute myeloid leukemia (AML) and multiple myeloma (MM).

Wugen Headquarter Location

4340 Duncan Ave Suite 302

Saint Louis, Missouri, 63110,

United States

Latest Wugen News

Wugen Presents New Preclinical Data from Novel Memory Natural Killer (NK) Platform at The Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting

Nov 12, 2021

11/12/2021 | 07:02am EST Message : *Required fields -- Wugen’s proprietary platform employs a GMP-grade, feeder cell-free manufacturing process to produce commercially scalable, off-the-shelf, non-engineered memory natural killer (NK) cell therapies with enhanced anti-tumor function -- -- Lead product candidate WU-NK-101 demonstrated potent anti-tumor activity and long-term persistence in vivo -- -- Data support ongoing clinical development of WU-NK-101 as best-in-class memory NK cell therapy for liquid and solid tumors -- Wugen, Inc. , a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today presented new data from its best-in-class memory natural killer (NK) cell therapy platform at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting. The presentation highlighted the preclinical development and proprietary manufacturing details of Wugen’s lead product candidate WU-NK-101 for the treatment of relapsed/refractory (r/r) acute myeloid leukemia (AML). The findings presented at SITC support development of WU-NK-101 as an off-the-shelf therapy for r/r AML and solid tumor indications. “These data showcase our differentiated approach to off-the-shelf cell therapies for cancer,” said Dan Kemp, Ph.D., President and Chief Executive Officer of Wugen. “Our memory NK cell platform is uniquely designed to overcome the limitations of existing cell therapy alternatives by delivering enhanced function, persistence, and ultimately efficacy without the need for feeder cells during the manufacturing process. Eliminating this step simplifies the process and allows us to deliver a safer product. We have prioritized manufacturing from the start and are proud that today’s data underscores our preparedness to deliver our product at-scale and provide powerful treatments to patients.” Today’s presentation highlighted the following: WU-NK-101 memory NK cells demonstrated robust cytotoxic efficacy in vitro, producing high levels of immune-activating cytokines and immune-attracting chemokines. WU-NK-101 showed strong anti-tumor activity in vivo, with long-term persistence and increased CD16 expression. WU-NK-101 drove robust antibody-dependent cell-mediated cytotoxicity (ADCC) activity against solid tumor cell lines in combination with approved therapeutic antibodies. Wugen’s process enables commercial-scale manufacturing of WU-NK-101 by using WU-PRIME, a single GMP-grade fusion protein complex, and WU-EXPAND, a feeder cell-free expansion system, in combination with a proprietary cryopreservation method to maintain an enhanced memory phenotype and preserve functionality. The details of Wugen’s presentation at SITC are as follows: Title: Development of WU-NK-101, a feeder cell-free expanded allogeneic memory NK cell product with potent anti-tumor activity Presenting Author: Mary E. Mathyer, Ph.D. Abstract Number: 188 Additional meeting information can be found on the SITC website at: https://www.sitcancer.org/2021/home . The poster will be available on the “Scientific Publications” section of Wugen’s website. About Wugen Wugen, Inc., is a clinical-stage biotechnology company developing a pipeline of off-the-shelf memory NK and CAR-T cell therapies to treat a broad range of hematological and solid tumor malignancies. Memory NK cells are hyper-functional, long-lasting immune cells that have evolved to attack cancer and respond to infection. Wugen is harnessing the power of this rare cell population by using its proprietary technologies to create WU-NK-101, currently in clinical development for acute myelogenous leukemia (AML). Wugen is also advancing WU-CART-007, an allogeneic CAR-T currently in development for T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (LBL). For more information, please visit www.wugen.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20211112005238/en/ © Business Wire 2021

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Wugen

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Wugen is included in 1 Expert Collection, including Regenerative Medicine.

R

Regenerative Medicine

1,767 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Wugen Patents

Wugen has filed 1 patent.

The 3 most popular patent topics include:

  • Cancer treatments
  • Clusters of differentiation
  • Immune system
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/8/2019

Clusters of differentiation, Olfactory receptors, Immune system, Immunology, Cancer treatments

Application

Application Date

11/8/2019

Grant Date

Title

Related Topics

Clusters of differentiation, Olfactory receptors, Immune system, Immunology, Cancer treatments

Status

Application

Wugen Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Wugen Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.